California startup Apama Medical raised $3.2 million in a Series A-1 financing round in support of a catheter-based technology that the company says is "vastly superior" in treatment of atrial fibrillation.
The company offered few details about the device in the press release or on its minimal website, but noted that it hopes to enter an atrial fibrillation mapping and ablation market that it expects to reach $2 billion by 2017.
The funding round was a coast-to-coast effort, with financing led by Boston-based Broadview Ventures.
Apama Medical grew out of Shifamed LLC, a technology incubator focused on bring medical technologies "from concept to commercial release," according to a company statement.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.